MetroHealth sues opioid makers to recoup addiction care costs

Cleveland-based MetroHealth is suing opioid manufacturers, including Purdue Pharma and Teva Pharmaceuticals, in an effort to reclaim care costs for overdose and opioid-addicted patients, Cleveland.com reports.

Advertisement

“As the healthcare provider for all of Cuyahoga county’s population, we are unfortunately in the position to see some of the most devastating results of the opioid epidemic,” said Joan Papp, MD, who leads MetroHealth’s office of opioid safety.

The health system’s filing names about a dozen opioid drug manufacturers, accusing them of deceptive marketing practices that led physicians to believe opioids are not as addictive as they are.

MetroHealth alleges it has incurred substantial costs in caring for those affected by overdoses and drug addiction, including increased hospitalizations, longer patient stays for addiction treatment and neonatal care for opioid-exposed newborns.

The filing does not specify a dollar amount for damages.

More articles on legal and regulatory issues:
Erlanger sues TennCare, claims state Medicaid program puts insurers before safety-net hospitals
Fake nurse in Maryland submitted thousands of false Medicaid claims, authorities say
U of Iowa ordered to pay $21.5M to children’s hospital contractor

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Download Whitepaper

The cost-saving opportunity most health systems overlook

Many hospitals and health systems scrutinize staffing, service lines, and payer contracts for savings. Fewer look at one of their largest assets: real estate.…

Advertisement

Next Up in Legal & Regulatory Issues

Advertisement

Comments are closed.